109 related articles for article (PubMed ID: 14732315)
21. Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model.
Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH; Firsov AA
Int J Antimicrob Agents; 2007 Feb; 29(2):165-9. PubMed ID: 17207607
[TBL] [Abstract][Full Text] [Related]
22. Testing the mutant selection window in rabbits infected with methicillin-resistant Staphylococcus aureus exposed to vancomycin.
Zhu YL; Hu LF; Mei Q; Cheng J; Liu YY; Ye Y; Li JB
J Antimicrob Chemother; 2012 Nov; 67(11):2700-6. PubMed ID: 22809703
[TBL] [Abstract][Full Text] [Related]
23. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
Lepak AJ; Andes DR
Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
[TBL] [Abstract][Full Text] [Related]
24. In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus.
Firsov AA; Golikova MV; Strukova EN; Portnoy YA; Romanov AV; Edelstein MV; Zinner SH
Antimicrob Agents Chemother; 2015 Feb; 59(2):1014-9. PubMed ID: 25451050
[TBL] [Abstract][Full Text] [Related]
25. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH
J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
[TBL] [Abstract][Full Text] [Related]
26. The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
Ebisu H; Kishii R; Takei M; Fukuda H
J Infect Chemother; 2003 Sep; 9(3):210-4. PubMed ID: 14513387
[TBL] [Abstract][Full Text] [Related]
27. Comparative mutant prevention concentration and mechanism of resistance to veterinary fluoroquinolones in Staphylococcus pseudintermedius.
Awji EG; Tassew DD; Lee JS; Lee SJ; Choi MJ; Reza MA; Rhee MH; Kim TH; Park SC
Vet Dermatol; 2012 Aug; 23(4):376-80, e68-9. PubMed ID: 22409306
[TBL] [Abstract][Full Text] [Related]
28. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
Firsov AA; Lubenko IY; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
[TBL] [Abstract][Full Text] [Related]
29. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin.
Firsov AA; Zinner SH; Vostrov SN; Portnoy YA; Lubenko IY
J Antimicrob Chemother; 2002 Oct; 50(4):533-9. PubMed ID: 12356798
[TBL] [Abstract][Full Text] [Related]
30. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model.
Firsov AA; Alieva KN; Strukova EN; Golikova MV; Portnoy YA; Dovzhenko SA; Kobrin MB; Romanov AV; Edelstein MV; Zinner SH
J Antimicrob Chemother; 2017 Nov; 72(11):3100-3107. PubMed ID: 28981793
[TBL] [Abstract][Full Text] [Related]
31. Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and Streptococci of lancefield groups A and G.
MacGowan AP; Bowker KE; Wootton M; Holt HA
J Antimicrob Chemother; 1999 Dec; 44(6):761-6. PubMed ID: 10590276
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.
Ince D; Hooper DC
Antimicrob Agents Chemother; 2001 Oct; 45(10):2755-64. PubMed ID: 11557465
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
[TBL] [Abstract][Full Text] [Related]
34. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
Lubenko IY; Strukova EV; Smirnova MV; Vostrov SN; Portnoy YA; Zinner SH; Firsov AA
J Antimicrob Chemother; 2008 Nov; 62(5):1065-9. PubMed ID: 18635520
[TBL] [Abstract][Full Text] [Related]
35. Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships.
Zinner SH; Vostrov SN; Lubenko IY; Portnoy YA; Cornaglia G; Firsov AA
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):167-71. PubMed ID: 11576789
[TBL] [Abstract][Full Text] [Related]
36. In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.
Lepak AJ; Marchillo K; Craig WA; Andes DR
Antimicrob Agents Chemother; 2015 Feb; 59(2):1258-64. PubMed ID: 25512404
[TBL] [Abstract][Full Text] [Related]
37. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
[TBL] [Abstract][Full Text] [Related]
38. Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.
Kesteman AS; Ferran AA; Perrin-Guyomard A; Laurentie M; Sanders P; Toutain PL; Bousquet-Mélou A
Antimicrob Agents Chemother; 2009 Nov; 53(11):4740-8. PubMed ID: 19738020
[TBL] [Abstract][Full Text] [Related]
39. Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.
Fung-Tomc J; Gradelski E; Huczko E; Minassian B; Bonner DP
Int J Antimicrob Agents; 2001 Jul; 18(1):77-80. PubMed ID: 11463531
[TBL] [Abstract][Full Text] [Related]
40. Using In Vitro Dynamic Models To Evaluate Fluoroquinolone Activity against Emergence of Resistant Salmonella enterica Serovar Typhimurium.
Lee SJ; Awji EG; Park NH; Park SC
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
